TLPPF (Telix Pharmaceuticals) PEG Ratio: N/A (As of Jun. 28, 2026)


TLPPF Telix Pharmaceuticals Ltd TLPPF
66 GF Score
Price $10.00
GF Value $27.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Telix Pharmaceuticals's PE Ratio without NRI is 0.00. Telix Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, Telix Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Telix Pharmaceuticals's PEG Ratio or its related term are showing as below:



TLPPF's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.92
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Telix Pharmaceuticals  (OTCPK:TLPPF) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Telix Pharmaceuticals PEG Ratio Related Terms


Telix Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals PEG Ratio Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TLPPF vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Telix Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's PEG Ratio falls into.


TLPPF
66GF Score
Telix Pharmaceuticals Ltd TLPPF
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Telix Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Telix Pharmaceuticals (TLPPF) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.00 is trading 64.1% below its estimated GF Value™ of $27.87. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLPPF:

  • PEG Ratio: N/A
  • GF Value™: $27.87 vs. price of $10.00 (64.1% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the TLPPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
66GF Score

Get the complete analysis for TLPPF

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$27.87
GF Value